Menu
Recruiting NCT06949891

KETOgenic Diet Therapy in Patients With ACROmegaly

No phase Interventional Acromegaly Due to Pituitary Adenoma Ketogenic Diet Mediterranean Diet

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ketogenic diet, Mediterranean diet.
Who it may be relevant to
Registry conditions: Acromegaly Due to Pituitary Adenoma, Ketogenic Diet, Mediterranean Diet. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Netherlands
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Ketogenic Diet Therapy in Patients With Acromegaly

Overview

Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH). Symptoms caused by the excess of GH, and consequently increased insulin like growth factor 1 (IGF-1), are disproportionate growth of body parts, fluid retention, snoring and excessive perspiration. The various metabolic changes that occur due to acromegaly increase the risk for insulin resistance, diabetes mellitus, arterial hypertension, sleep apnoea and thus an increased risk of cardiovascular disease if left untreated. The result is signs and symptoms, increased mortality, morbidity, and greatly reduced quality of life (QoL). Normalisation of GH and IGF-1 gives a normalisation of mortality, however morbidity and QoL do not (completely) normalise. After surgery, a somatostatin analogue is the primary medical treatment, however, normalisation occurs in only 40% of patients. Recently, in a proof-of-principle study, the researchers showed that a 2-week ketogenic diet (low in carbohydrates) in patients with somatostatin analogues could significantly reduce IGF-1 values. Patients felt better and sometimes even needed less somatostatin analogues. This proof of concept led to the new hypothesis that acromegaly patients with somatostatin analogues should possibly be treated with a eucaloric low-carbohydrate ketogenic diet for a longer period of time to improve their biochemistry, symptoms and QoL. Additionally, this diet can make a significant contribution in the treatment of insulin resistance and glucose intolerance that often occur in this patient group.

Interventions

  • Dietary supplement Ketogenic diet
    A eucaloric ketogenic diet (30-40 g carbohydrate per day) for 3 months, followed by a less strict ketogenic diet (50-60 g carbohydrate per day) for another 3 months.
  • Dietary supplement Mediterranean diet
    The control group will receive a eucaloric diet according to the national healthy food guidelines/Mediterranean diet.

Primary outcome measures

  • IGF-1 [Time frame: At baseline, 3 months and 6 months.]

Eligibility criteria

Inclusion criteria

  • Male or female, 18 years or older
  • Diagnosis of acromegaly based on elevated GH and/or IGF-I levels due to a pituitary tumor
  • IGF-I levels above 80% upper limit of the normal range (xULN)) on a stable medication dose for at least 4 months
  • Written informed consent

Exclusion criteria

  • Pregnancy or breastfeeding
  • Pegvisomant treatment
  • Has undergone pituitary surgery or radiotherapy within 6 months prior to s study entry;
  • It is anticipated that the patient will receive pituitary surgery or radiotherapy during the study;
  • History or presence of epilepsy;
  • Participation in a trail of an experimental drug or device within 30 days prior to screening;
  • Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study
  • Screening HbA1c > 6,5%;
  • Use of antidiabetic medication other than Metformin

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Netherlands · 1 center
  • Erasmus Medical Center — Rotterdam

Identifiers

NCT: NCT06949891 · NL8384107823

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗